Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luis G Paz-Ares

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
BMC Cancer|March 10, 2010
Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancerLuis G Paz-Ares, Sedat Altug, Alexandra Thareau Vaury, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancerLuis G Paz-Ares, Annamaria Zimmermann, Tudor Ciuleanu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Pemetrexed safety and pharmacokinetics in patients with third-space fluidNicolas J Dickgreber, Jens Benn Sorensen, Luis G Paz-Ares, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2014
PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancerMartin Reck, Luis G Paz-Ares, Filippo de Marinis, et al.
Clinical Lung Cancer|February 27, 2026
TIGOS Trial: A Randomized, Double-Blind, Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as First-Line Therapy in Patients With Extensive-Stage Small Cell Lung CancerLuis G Paz-Ares, Kenneth John O'Byrne, Melissa L Johnson, et al.
Lung Cancer (Amsterdam, Netherlands)|July 18, 2025
Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doubletAstrid Paulus, Marius Zemaitis, Saulius Cicenas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancerDaniel D Karp, Luis G Paz-Ares, Silvia Novello, et al.
Clinical Lung Cancer|May 9, 2017
Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III StudiesCorey J Langer, Luis G Paz-Ares, Antoinette J Wozniak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2011
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumorsLuis G Paz-Ares, Carlos Gomez-Roca, Jean-Pierre Delord, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2014
Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III studyCesare Gridelli, Filippo de Marinis, Michael Thomas, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
BMC Cancer|March 10, 2010
Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancerLuis G Paz-Ares, Sedat Altug, Alexandra Thareau Vaury, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancerLuis G Paz-Ares, Annamaria Zimmermann, Tudor Ciuleanu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Pemetrexed safety and pharmacokinetics in patients with third-space fluidNicolas J Dickgreber, Jens Benn Sorensen, Luis G Paz-Ares, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2014
PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancerMartin Reck, Luis G Paz-Ares, Filippo de Marinis, et al.
Clinical Lung Cancer|February 27, 2026
TIGOS Trial: A Randomized, Double-Blind, Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as First-Line Therapy in Patients With Extensive-Stage Small Cell Lung CancerLuis G Paz-Ares, Kenneth John O'Byrne, Melissa L Johnson, et al.
Lung Cancer (Amsterdam, Netherlands)|July 18, 2025
Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doubletAstrid Paulus, Marius Zemaitis, Saulius Cicenas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancerDaniel D Karp, Luis G Paz-Ares, Silvia Novello, et al.
Clinical Lung Cancer|May 9, 2017
Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III StudiesCorey J Langer, Luis G Paz-Ares, Antoinette J Wozniak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2011
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumorsLuis G Paz-Ares, Carlos Gomez-Roca, Jean-Pierre Delord, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2014
Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III studyCesare Gridelli, Filippo de Marinis, Michael Thomas, et al.
Pageof 4